| abstract |
The present invention relates to an FGFR4 inhibitor having the structure of formula (I) and a method for producing and using the same. The definition of each substituent in the formula is as described in the description and the claims. The series of compounds of the formula (I) developed in the present invention have a strong inhibitory effect on the activity of FGFR4 kinase and have a very high selectivity, and are particularly suitable for cancer, especially prostate cancer, liver cancer, pancreatic gland A new generation of FGFR4 inhibitors that can be widely applied in the manufacture of drugs to treat cancer, esophageal cancer, gastric cancer, lung cancer, breast cancer, ovarian cancer, colon cancer, skin cancer, glioblastoma or rhabdomyosarcoma It is expected to be developed as a drug. Embedded image |